Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FCER2 | P06734 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103486 | 1.00 | KDM1A (0.58) | KDM1AMAOAHDAC8HDAC3HDAC4 | |
| SCHEMBL29802269 | 1.00 | KDM1A (0.58) | KDM1AMAOAHDAC8HDAC3HDAC4 | |
| SCHEMBL7860801 | 0.83 | LTA4H (0.51) | KDM1AMAOAHDAC8HDAC3HDAC4 | |
| SCHEMBL7859203 | 0.82 | LTA4H (0.55) | KDM1AMAOATRHDESMN1; SMN2FCER2 | |
| SCHEMBL13865248 | 0.82 | MEN1 (0.54) | KDM1AMAOATRHDEMEN1KMT2A | |
| SCHEMBL12856056 | 0.82 | MEN1 (0.54) | KDM1AMAOATRHDEMEN1KMT2A | |
| SCHEMBL9489894 | 0.81 | MEN1 (0.49) | HDAC4HDAC1SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL2306692 | 0.81 | PIN1 (0.50) | FCER2 | |
| SCHEMBL1614525 | 0.80 | BACE1 (0.54) | HDAC8SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL5145729 | 0.80 | BACE1 (0.54) | HDAC8SMN1; SMN2MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409935-A1 | Atg8ylation coordinates stress granule formation and mTOR inactivation in response to lysosomal damage | UNM RAINFOREST INNOVATIONS (US) | 2024-12-12 | — | — | US | claimed |
| US-20210069295-A1 | GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-11 | — | — | US | claimed |
| US-20240409935-A1 | Atg8ylation coordinates stress granule formation and mTOR inactivation in response to lysosomal damage | UNM RAINFOREST INNOVATIONS (US) | 2024-12-12 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-20210069295-A1 | GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-11 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3515477-A1 | MODULATION OF FUNCTION OF IMMUNE EFFECTOR CELLS | Oslo Universitetssykehus HF (NO) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225941-A1 | MODULATION OF FUNCTION OF IMMUNE EFFECTOR CELLS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2019-07-25 | — | — | US | disclosed |
| WO-2018055152-A1 | MODULATION OF FUNCTION OF IMMUNE EFFECTOR CELLS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2018-03-29 | — | — | WO | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409935-A1 | Atg8ylation coordinates stress granule formation and mTOR inactivation in response to lysosomal damage | LAMTOR3, MLST8, ATG7 | KDM1A 3286/4885MAOA 4752/4885HDAC8 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.